Ramosetron
Hydrochloride Market by Indication (Motion Sickness, Irritable Bowel Syndrome,
Cancer Chemotherapy associated Nausea and Vomiting, and, Diarrhoea), by
Application (Hospitals, Clinics, and Home Care), and by Geography (North
America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size,
Share, Outlook, and Opportunity Analysis 2018 – 2026
Ramosetron hydrochloride, an
anti-emetic drug, is prescribed for the treatment of diarrhoea-predominant
irritable bowel syndrome in adults. Ramosetron hydrochloride is also prescribed
for the treatment and management of postoperative nausea and/or vomiting and
also associated with carcinostatic drugs including cisplatin.
Ramosetron Hydrochloride Market
Driver
Rising research activities for
ramosetron hydrochloride is estimated to propel the growth of ramosetron
hydrochloride in the global market over projected year. For instance, according
to Gastroenterology February 2016, study has shown that ramosetron is expected
to reduce symptoms of irritable bowel syndrome with diarrhea and improves
quality of life in women. Ramosetron have shown to improve stool consistency in
women. This rising research for use of ramosetron can drive the growth of
global ramosetron hydrochloride market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2289
Ramosetron Hydrochloride Market
Restraint
Adverse effects associated with
the drugs such as for instance, Current Index of Medical Specialties (CIMS)
2018 states, prolog use of ramosetron hydrochloride is associated with
headache, diarrhoea, constipation, allergic reactions, and severe hepatic
failures which can be fatal, and can restrain the growth of ramosetron
hydrochloride in the global market over forecasted year.
Ramosetron Hydrochloride Market –
Regional Analysis
Based on region, the global
ramosetron hydrochloride market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa.
North America region is
anticipated to dominant in the growth of global ramosetron hydrochloride market
attributed to prevalence of irritable bowel syndrome in U.S. For instance,
Centers for Disease Control and Prevention 2015 statistics estimated 1.3% of
U.S. adults (3 million) being diagnosed with irritable bowel syndrome.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/ramosetron-hydrochloride-market-2289
Asia Pacific region is estimated
to perceive noteworthy growth in the global Ramosetron Hydrochloride market
owing to rising approvals for licensing of drug by regulatory bodies. For
instance, in April 2015, Ministry of Health, Labour and Welfare, Japan, and
Pharmaceuticals and Medical Devices Agency (PMDA) concluded that ramosetron
hydrochloride, manufactured by Astellas Pharma Inc. is effective in patients
with diarrhea-predominant irritable bowel syndrome and the drug was approved
for marketing.
Ramosetron Hydrochloride Market –
Competitive Analysis
The key players of ramosetron
hydrochloride market include, Astellas Pharma Inc., Abbott Laboratories,
AdvaCare Pharma, Tioga Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc.,
Sucampo Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Pharmos Corporation,
Shandong Chenlong Pharmaceutical Co. Ltd, and Alomone Labs.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2289
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment